Showing results (201-210 of 216) with videos related to

Sort By:
Pageof 22
European Journal of Heart Failure|April 11, 2017
Effect of intracoronary administration of AAV1/SERCA2a on ventricular remodelling in patients with advanced systolic heart failure: results from the AGENT-HF randomized phase 2 trialJean-Sébastien Hulot, Joe-Elie Salem, Alban Redheuil, et al.
JCI Insight|July 2, 2024
Single-cell RNA-Seq analysis reveals cell subsets and gene signatures associated with rheumatoid arthritis disease activityMarie Binvignat, Brenda Y Miao, Camilla Wibrand, et al.
NEJM Evidence|February 6, 2024
Regulatory T-Cell Response to Low-Dose Interleukin-2 in Ischemic Heart DiseaseTian X Zhao, Rouchelle S Sriranjan, Zewen Kelvin Tuong, et al.
Annals of the Rheumatic Diseases|November 26, 2018
Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trialMichelle Rosenzwajg, Roberta Lorenzon, Patrice Cacoub, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 14, 2025
Immunological Profiling suggests an Association between Treg dysfunction and Pain in Knee OsteoarthritisMarie Binvignat, Johanna Dubois, Maria Marco Salvador, et al.
Human Gene Therapy|December 22, 2004
Phase I study of dystrophin plasmid-based gene therapy in Duchenne/Becker muscular dystrophyNorma B Romero, Serge Braun, Olivier Benveniste, et al.
BMJ Open|September 1, 2018
Clinical and multi-omics cross-phenotyping of patients with autoimmune and autoinflammatory diseases: the observational TRANSIMMUNOM protocolRoberta Lorenzon, Encarnita Mariotti-Ferrandiz, Caroline Aheng, et al.
Brain : a Journal of Neurology|January 14, 2012
A phase I trial of adeno-associated virus serotype 1-γ-sarcoglycan gene therapy for limb girdle muscular dystrophy type 2CSerge Herson, Faycal Hentati, Aude Rigolet, et al.
Frontiers in Immunology|November 23, 2017
Reproducibility and Reuse of Adaptive Immune Receptor Repertoire DataFelix Breden, Eline T Luning Prak, Bjoern Peters, et al.
Cell Research|January 14, 2015
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25Dalil Hannani, Marie Vétizou, David Enot, et al.
Pageof 22